HK1029529A1 - Novel process for manufacturing paroxetine solid dispersions - Google Patents

Novel process for manufacturing paroxetine solid dispersions

Info

Publication number
HK1029529A1
HK1029529A1 HK01100318A HK01100318A HK1029529A1 HK 1029529 A1 HK1029529 A1 HK 1029529A1 HK 01100318 A HK01100318 A HK 01100318A HK 01100318 A HK01100318 A HK 01100318A HK 1029529 A1 HK1029529 A1 HK 1029529A1
Authority
HK
Hong Kong
Prior art keywords
novel process
solid dispersions
manufacturing
manufacturing paroxetine
paroxetine solid
Prior art date
Application number
HK01100318A
Other languages
English (en)
Inventor
Philip J Krape
Sou-Chan Chang
William A Ii Hein
Christopher A Teleha
Original Assignee
Endo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Pharmaceuticals Inc filed Critical Endo Pharmaceuticals Inc
Publication of HK1029529A1 publication Critical patent/HK1029529A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK01100318A 1997-06-30 2001-01-12 Novel process for manufacturing paroxetine solid dispersions HK1029529A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/885,068 US5955475A (en) 1997-06-30 1997-06-30 Process for manufacturing paroxetine solid dispersions
PCT/US1998/013350 WO1999000131A1 (en) 1997-06-30 1998-06-26 Novel process for manufacturing paroxetine solid dispersions

Publications (1)

Publication Number Publication Date
HK1029529A1 true HK1029529A1 (en) 2001-04-06

Family

ID=25386061

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01100318A HK1029529A1 (en) 1997-06-30 2001-01-12 Novel process for manufacturing paroxetine solid dispersions

Country Status (23)

Country Link
US (1) US5955475A (ko)
EP (1) EP0991408B1 (ko)
JP (1) JP2002514227A (ko)
KR (1) KR100571044B1 (ko)
CN (1) CN1121219C (ko)
AP (1) AP9901725A0 (ko)
AR (1) AR013131A1 (ko)
AT (1) ATE290381T1 (ko)
AU (1) AU733194B2 (ko)
BR (1) BR9810231A (ko)
CA (1) CA2295752C (ko)
DE (1) DE69829286T2 (ko)
ES (1) ES2239395T3 (ko)
HK (1) HK1029529A1 (ko)
MA (1) MA24589A1 (ko)
NO (1) NO996484L (ko)
NZ (1) NZ502062A (ko)
OA (1) OA11518A (ko)
RU (1) RU2185820C2 (ko)
SA (1) SA98190227A (ko)
TR (1) TR199903315T2 (ko)
WO (1) WO1999000131A1 (ko)
ZA (1) ZA985488B (ko)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638948B1 (en) * 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
SI0994872T1 (ko) * 1997-06-10 2001-08-31 Synthon Bv
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
US6168805B1 (en) 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
AU3810100A (en) * 1999-03-12 2000-10-04 Basf Aktiengesellschaft Stable pharmaceutical application form for paroxetin anhydrate
DE19930454A1 (de) * 1999-07-02 2001-01-04 Knoll Ag Feste Paroxetin enthaltende Zubereitungen
US6503927B1 (en) * 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
DE60028754T2 (de) * 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US20030104065A1 (en) * 2000-03-09 2003-06-05 Arne Brodin Method of preparing solid dispersions
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20030212105A1 (en) * 2000-12-07 2003-11-13 Agrawal Shyam Sunder Novel anti-fertility agent
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
WO2002085360A1 (en) * 2001-04-25 2002-10-31 Pentech Pharmaceuticals, Inc. Optimized procedures for the manufacture of paroxetine salts
US20030170309A1 (en) * 2001-06-22 2003-09-11 Babcock Walter C. Pharmaceutical compositions containing polymer and drug assemblies
PL368587A1 (en) * 2001-06-22 2005-04-04 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
EP1412350A1 (en) * 2001-08-02 2004-04-28 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
CA2470496A1 (en) * 2001-12-28 2003-07-17 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
KR100691608B1 (ko) * 2005-02-21 2007-03-12 (주)나노하이브리드 염기성 고분자가 첨가된 유리 염기형 약물과 층상형 규산염의 하이브리드 및 그의 제조방법
WO2007015270A2 (en) * 2005-08-02 2007-02-08 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
EP1948646A2 (en) * 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
WO2008067164A2 (en) * 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
JP5484910B2 (ja) 2006-12-22 2014-05-07 ユーハン・コーポレイション レバプラザン含有の固体分散体及びその製造方法
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
JP5700367B2 (ja) * 2010-05-06 2015-04-15 高田製薬株式会社 パロキセチン含有フイルムコ−テイング経口製剤
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US9381199B2 (en) 2012-07-09 2016-07-05 Hetero Research Foundation Linagliptin solid dispersion
WO2014009970A2 (en) * 2012-07-09 2014-01-16 Hetero Research Foundation Linagliptin solid dispersion
US10206874B2 (en) 2012-07-20 2019-02-19 Hetero Research Foundation Rufinamide solid dispersion
US9211290B2 (en) * 2012-12-31 2015-12-15 Noven Therapeutics, Llc Solid dispersions of amorphous paroxetine mesylate
CN110114063B (zh) * 2017-01-06 2022-01-11 广东东阳光药业有限公司 鲁拉西酮固体分散体及其制备方法
RU2698400C1 (ru) * 2018-12-17 2019-08-26 Георгий Сергеевич Немов Способ лечения депрессии у собак и кошек

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5147733B2 (ko) * 1974-02-15 1976-12-16
DD220225A5 (de) * 1983-03-16 1985-03-27 Boehringer Ingelheim Ltd Verfahren zur herstellung einer festkoerperdispersion von chlorthalidon
US4933360A (en) * 1983-03-16 1990-06-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel chlorthalidone process and product
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
DE69222847T3 (de) * 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
DE69222182T2 (de) * 1991-12-18 1998-02-26 Warner Lambert Co Verfahren für die herstellung einer festen dispersion
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
JP3768536B2 (ja) * 1995-04-03 2006-04-19 アボツト・ラボラトリーズ 低温溶融性薬物と制御放出のための添加物との均質混合物
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
EP0991408B1 (en) 2005-03-09
DE69829286D1 (de) 2005-04-14
JP2002514227A (ja) 2002-05-14
ZA985488B (en) 1999-04-22
AU8171798A (en) 1999-01-19
KR100571044B1 (ko) 2006-04-13
EP0991408A4 (en) 2003-07-09
WO1999000131A1 (en) 1999-01-07
NZ502062A (en) 2001-10-26
OA11518A (en) 2004-02-04
SA98190227A (ar) 2005-12-03
AU733194B2 (en) 2001-05-10
TR199903315T2 (xx) 2000-09-21
KR20010020592A (ko) 2001-03-15
DE69829286T2 (de) 2006-01-12
CN1265593A (zh) 2000-09-06
BR9810231A (pt) 2000-08-08
AR013131A1 (es) 2000-12-13
ES2239395T3 (es) 2005-09-16
AP9901725A0 (en) 1999-12-31
CN1121219C (zh) 2003-09-17
MA24589A1 (fr) 1998-12-31
RU2185820C2 (ru) 2002-07-27
NO996484L (no) 2000-02-25
EP0991408A1 (en) 2000-04-12
US5955475A (en) 1999-09-21
CA2295752C (en) 2004-10-26
ATE290381T1 (de) 2005-03-15
CA2295752A1 (en) 1999-01-07
NO996484D0 (no) 1999-12-27

Similar Documents

Publication Publication Date Title
ZA985488B (en) Novel process for manufacturing paroxetine solid dispersions
GB9827387D0 (en) Novel process
GB9714383D0 (en) Improved process
GB9826180D0 (en) Novel process
GB9914583D0 (en) Novel process
HUP0004503A3 (en) Process for the preparation of paroxetine hydrochloride
GB9826242D0 (en) Novel process
HUP9900761A3 (en) A process for the preparation of 4-(desdimethyl-amino)-tetracyclines
AU1396400A (en) Process for the preparation of paroxetine hydrochloride
AU6481799A (en) Process for the preparation of paroxetine hydrochloride
HUP0003060A3 (en) Process for preparing 2-halogenated indan-1-ones
GB9916392D0 (en) Novel process
MD810F1 (en) Process for modified ionites obtaining
GB9817195D0 (en) Novel process
GB9826178D0 (en) Novel process
GB9916187D0 (en) Novel process
GB9828767D0 (en) Novel process
GB9806786D0 (en) Novel process
GB9828780D0 (en) Novel process
GB9828779D0 (en) Novel process
GB9915303D0 (en) Novel process
AU1396600A (en) Process for the preparation of paroxetine hydrochloride
GB9807834D0 (en) Novel process
GB9816027D0 (en) Novel process
GB9826182D0 (en) Novel process

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090626